Policy
The $1.2 trillion budget package will now move to the Senate, which is expected to hold a vote next week.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former US Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
ISCT, the International Society for Cell and Gene Therapy announces its objection to linking the benefits of cellular immunotherapy, in particular Chimeric Antigen Receptor T-cell therapy, with recent market offerings for third party cryopreserving and banking of T-cells for future therapeutic use.
Myriad Genetics, Inc. announced that the AstraZeneca/Merck Phase III PROfound studydemonstrated that men with metastatic castration-resistant prostate cancer who tested positive for germline and somatic mutations in homologous recombination repair genes benefitted from treatment with Lynparza®, a novel PARP inhibitor.
Former Touch Bionics CEO joins Adapttech as company secures FDA decision for medical device that improves prosthesis fit
Epigenomics AG announced the operational achievements plus financial results for the second quarter and the first half of 2019.
Quanta Dialysis Technologies Ltd, a British medical technology company developing a personal haemodialysis system for patient use in the clinic and the home, announces that it has begun human factors testing of SC+ in the United States with Design Science, a leading specialist in medical device usability.
Conference call and webcast, August 07, 2019 at 3:00 pm CET, 9:00 am EST
Researchers from A*STAR’s Institute of Bioengineering and Nanotechnology have successfully developed an innovative nanocarrier derived from green tea catechins, which can deliver anti-cancer drugs in a targeted and effective fashion.
MorphoSys AG announced its intention to submit a Marketing Authorization Application to the European Medicines Agency based on its phase 2 L-MIND study of tafasitamab and lenalidomide in relapsed or refractory diffuse large B cell lymphoma.
Retrophin, Inc. reported its second quarter 2019 financial results and provided a corporate update.
Despite the data concerns, the U.S. Food and Drug Administration said it believes the gene therapy should remain on the market. Novartis said it stands behind the safety and efficacy of the therapy.